🤔Best tx option for this Stage III (T4N2) NSCLC?
A) Neoadj chemo->OR->osi
B) ChemoRT then osimertinib
C) ChemoRT then durvalumab
D) Neoadjuvant osimertinib and reassess
A) Neoadj chemo->OR->osi
B) ChemoRT then osimertinib
C) ChemoRT then durvalumab
D) Neoadjuvant osimertinib and reassess
December 11, 2024 at 1:07 AM
🤔Best tx option for this Stage III (T4N2) NSCLC?
A) Neoadj chemo->OR->osi
B) ChemoRT then osimertinib
C) ChemoRT then durvalumab
D) Neoadjuvant osimertinib and reassess
A) Neoadj chemo->OR->osi
B) ChemoRT then osimertinib
C) ChemoRT then durvalumab
D) Neoadjuvant osimertinib and reassess
FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial:
- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP
www.fda.gov/drugs/resour...
#MedSky #OncSky #LcSM @oncoalert.bsky.social
- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP
www.fda.gov/drugs/resour...
#MedSky #OncSky #LcSM @oncoalert.bsky.social
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
www.fda.gov
December 5, 2024 at 7:58 AM
FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial:
- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP
www.fda.gov/drugs/resour...
#MedSky #OncSky #LcSM @oncoalert.bsky.social
- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP
www.fda.gov/drugs/resour...
#MedSky #OncSky #LcSM @oncoalert.bsky.social
1/Compared to standard chemoradiation (chemoRT), adding pembrolizumab during and continuing after chemoRT improves overall survival. 2/7
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
November 27, 2024 at 12:26 PM
1/Compared to standard chemoradiation (chemoRT), adding pembrolizumab during and continuing after chemoRT improves overall survival. 2/7
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
5/29 #TumorBoardTuesday
👩🏫Mini tweetorial 4 👨🏫
👉PACIFIC regimen = SOC for Stage IIIB NSCLC
🧐No OS benefit for EGFRm subset..
💁♀️LAURA
⭐️Phase III - osi after chemoRT
⭐️Unresectable stage III EGFRm NSCLC
👏Osi vs placebo➡️med PFS 39.1 vs 5.6 mo
🏆Osi after chemoRT = new SOC
👩🏫Mini tweetorial 4 👨🏫
👉PACIFIC regimen = SOC for Stage IIIB NSCLC
🧐No OS benefit for EGFRm subset..
💁♀️LAURA
⭐️Phase III - osi after chemoRT
⭐️Unresectable stage III EGFRm NSCLC
👏Osi vs placebo➡️med PFS 39.1 vs 5.6 mo
🏆Osi after chemoRT = new SOC
December 11, 2024 at 1:14 AM
5/29 #TumorBoardTuesday
👩🏫Mini tweetorial 4 👨🏫
👉PACIFIC regimen = SOC for Stage IIIB NSCLC
🧐No OS benefit for EGFRm subset..
💁♀️LAURA
⭐️Phase III - osi after chemoRT
⭐️Unresectable stage III EGFRm NSCLC
👏Osi vs placebo➡️med PFS 39.1 vs 5.6 mo
🏆Osi after chemoRT = new SOC
👩🏫Mini tweetorial 4 👨🏫
👉PACIFIC regimen = SOC for Stage IIIB NSCLC
🧐No OS benefit for EGFRm subset..
💁♀️LAURA
⭐️Phase III - osi after chemoRT
⭐️Unresectable stage III EGFRm NSCLC
👏Osi vs placebo➡️med PFS 39.1 vs 5.6 mo
🏆Osi after chemoRT = new SOC
Second up! Dr. Jean Bourhis Sr presents NIVOPOSTOP (GORTEC 2018-01): chemoRT +/- nivolumab for resected, high risk head and neck squamous cell carcinoma. 24% risk reduction in disease progression or death: 3-year DFS 63.1 vs 52.5 months (HR 0.76) with substantial drop in locoregional relapse #ASCO25
June 1, 2025 at 6:45 PM
Second up! Dr. Jean Bourhis Sr presents NIVOPOSTOP (GORTEC 2018-01): chemoRT +/- nivolumab for resected, high risk head and neck squamous cell carcinoma. 24% risk reduction in disease progression or death: 3-year DFS 63.1 vs 52.5 months (HR 0.76) with substantial drop in locoregional relapse #ASCO25
Key Results from the ESO-Shanghai 17 and 9 Trials: Small T-Field Postoperative ChemoRT Shows Safer Profile in Resected ESCC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Key Results from the ESO-Shanghai 17 and 9 Trials: Small T-Field Postoperative ChemoRT Shows Safer Profile in Resected ESCC - OncoDaily
ESO-Shanghai 17: a 50.4 Gy small T-field matches ESO-9 outcomes while reducing toxicity and pneumonitis risk.
oncodaily.com
December 5, 2025 at 11:43 PM
Key Results from the ESO-Shanghai 17 and 9 Trials: Small T-Field Postoperative ChemoRT Shows Safer Profile in Resected ESCC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
2/Compared to standard chemoRT (blue), 6 weekly doses of chemo (induction, in red) followed by chemoRT improved OS. 4/7
November 27, 2024 at 12:26 PM
2/Compared to standard chemoRT (blue), 6 weekly doses of chemo (induction, in red) followed by chemoRT improved OS. 4/7
"more" locally advanced primary cervical cancers, give chemoRT and pembro.
For those in whom current data indicate pembro might not help, give induction chemo. 7/7
Thoughts??
#gyncsm
For those in whom current data indicate pembro might not help, give induction chemo. 7/7
Thoughts??
#gyncsm
November 27, 2024 at 12:26 PM
"more" locally advanced primary cervical cancers, give chemoRT and pembro.
For those in whom current data indicate pembro might not help, give induction chemo. 7/7
Thoughts??
#gyncsm
For those in whom current data indicate pembro might not help, give induction chemo. 7/7
Thoughts??
#gyncsm
#RealWorldData on OS differences for px with Stage III #NSCLC s/p #ChemoRT, eligible for #immunotherapy 2018-2020. Treatment facility & insurance = independent predictors of OS. ~54% received IO. IO receipt was associated with 47% mortality risk reduction. #ASCO26 @bidmc-cancercenter.bsky.social
May 30, 2026 at 8:31 PM
#RealWorldData on OS differences for px with Stage III #NSCLC s/p #ChemoRT, eligible for #immunotherapy 2018-2020. Treatment facility & insurance = independent predictors of OS. ~54% received IO. IO receipt was associated with 47% mortality risk reduction. #ASCO26 @bidmc-cancercenter.bsky.social
Excited to share our #RealWorldData and evidence on socioeconomic and clinical factors associated with OS in patients with Stage III #NSCLC following #chemoRT in the post-PACIFIC era! Stop by, 9am-12pm, 5/30! #ASCO2026 #LungCancer @ascocancer.bsky.social @bidmc-cancercenter.bsky.social @TuftsMedCtr
May 29, 2026 at 8:31 PM
Excited to share our #RealWorldData and evidence on socioeconomic and clinical factors associated with OS in patients with Stage III #NSCLC following #chemoRT in the post-PACIFIC era! Stop by, 9am-12pm, 5/30! #ASCO2026 #LungCancer @ascocancer.bsky.social @bidmc-cancercenter.bsky.social @TuftsMedCtr
11/29 #TumorBoardTuesday
Bx💉👉lung adeno (PD-L1 TPS 35%), R4 node+
🎯Negative NGS testing
Pt is fit 🏃♂️(ECOG 0)
🤨Best tx for this Stage IIIB (T4N2) NSCLC ?
A) Surgery then adj chemoIO
B) Neoadj chemoIO
C) PACIFIC approach
D) Neoadjuvant chemoRT
Bx💉👉lung adeno (PD-L1 TPS 35%), R4 node+
🎯Negative NGS testing
Pt is fit 🏃♂️(ECOG 0)
🤨Best tx for this Stage IIIB (T4N2) NSCLC ?
A) Surgery then adj chemoIO
B) Neoadj chemoIO
C) PACIFIC approach
D) Neoadjuvant chemoRT
December 11, 2024 at 1:27 AM
11/29 #TumorBoardTuesday
Bx💉👉lung adeno (PD-L1 TPS 35%), R4 node+
🎯Negative NGS testing
Pt is fit 🏃♂️(ECOG 0)
🤨Best tx for this Stage IIIB (T4N2) NSCLC ?
A) Surgery then adj chemoIO
B) Neoadj chemoIO
C) PACIFIC approach
D) Neoadjuvant chemoRT
Bx💉👉lung adeno (PD-L1 TPS 35%), R4 node+
🎯Negative NGS testing
Pt is fit 🏃♂️(ECOG 0)
🤨Best tx for this Stage IIIB (T4N2) NSCLC ?
A) Surgery then adj chemoIO
B) Neoadj chemoIO
C) PACIFIC approach
D) Neoadjuvant chemoRT
🔴Online now: ChemoRT vs short-course RT for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of a randomised, phase 2/3 trial
📉Article: thelancet.com/journals/lan...
&
✏️ Comment: thelancet.com/journals/lan...
📉Article: thelancet.com/journals/lan...
&
✏️ Comment: thelancet.com/journals/lan...
August 24, 2026 at 8:33 AM
🔴Online now: ChemoRT vs short-course RT for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of a randomised, phase 2/3 trial
📉Article: thelancet.com/journals/lan...
&
✏️ Comment: thelancet.com/journals/lan...
📉Article: thelancet.com/journals/lan...
&
✏️ Comment: thelancet.com/journals/lan...
RAD-io in MIBC: chemoRT + durvalumab achieves 80% DFS at 12 months (40/50 pts) vs ~60% historical benchmark.
Signal exceeds pre-set threshold for further study
Nick James
#ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky
Signal exceeds pre-set threshold for further study
Nick James
#ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky
May 30, 2026 at 2:21 PM
RAD-io in MIBC: chemoRT + durvalumab achieves 80% DFS at 12 months (40/50 pts) vs ~60% historical benchmark.
Signal exceeds pre-set threshold for further study
Nick James
#ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky
Signal exceeds pre-set threshold for further study
Nick James
#ASCO26 #BladderCancer #Oncology #MIBC #MedEd #MedSky
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Monday, June 8, 2026
Published on Monday, June 8, 2026
TESAR Trial: Adjuvant ChemoRT vs Completion TME After Local Excision for Early Rectal Cancer
TESAR Trial: Adjuvant ChemoRT vs Completion TME After Local Excision for Early Rectal Cancer / Adjuvant ChemoRT, cancer, cancer care, Cancer research, cancer
oncodaily.com
June 8, 2026 at 12:35 PM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Monday, June 8, 2026
Published on Monday, June 8, 2026
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Sunday, January 11, 2026
Published on Sunday, January 11, 2026
Nina Niu Sanford: CRITICS-II Raises New Questions on Adding ChemoRT to D-FLOT
Nina Niu Sanford: CRITICS-II Raises New Questions on Adding ChemoRT to D-FLOT / cancer, CRITICS-II, Nina Niu Sanford, OncoDaily, Oncology
oncodaily.com
January 11, 2026 at 12:16 AM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Sunday, January 11, 2026
Published on Sunday, January 11, 2026
Excited to be presenting our research #ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT:
meetings.asco.org/abstracts-pr...
@bidmcreseach.bsky.social
#TuftsMedicine
meetings.asco.org/abstracts-pr...
@bidmcreseach.bsky.social
#TuftsMedicine
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
April 23, 2025 at 4:14 PM
Excited to be presenting our research #ASCO meeting this year! Can't wait to share our findings on patterns of immunotherapy use in different groups of stage 3 NSCLC patients who were treated definitively with chemoRT:
meetings.asco.org/abstracts-pr...
@bidmcreseach.bsky.social
#TuftsMedicine
meetings.asco.org/abstracts-pr...
@bidmcreseach.bsky.social
#TuftsMedicine
Important phase III in #ESMO25, adding Nimotuzumab to chemoRT yielded no benefit in high risk resected head and neck cancer #MedIQESMO25 #HNSCC. RTOG 1216 ongoing assessing similar patient population
October 23, 2025 at 7:16 PM
Important phase III in #ESMO25, adding Nimotuzumab to chemoRT yielded no benefit in high risk resected head and neck cancer #MedIQESMO25 #HNSCC. RTOG 1216 ongoing assessing similar patient population
In @swog.org group mtg GU cmte session, Dr. Leslie Ballas presents on S2427 BRIGHT trial, activating this summer. Bladder preserv w chemoRT or IO-RT after good response to neoadjuvant chemo in patients w muscle invasive #bladdercancer.
Do pts who respond to neoadjuv chemo need cystectomy? #SWOGonc
Do pts who respond to neoadjuv chemo need cystectomy? #SWOGonc
May 3, 2025 at 5:45 PM
In @swog.org group mtg GU cmte session, Dr. Leslie Ballas presents on S2427 BRIGHT trial, activating this summer. Bladder preserv w chemoRT or IO-RT after good response to neoadjuvant chemo in patients w muscle invasive #bladdercancer.
Do pts who respond to neoadjuv chemo need cystectomy? #SWOGonc
Do pts who respond to neoadjuv chemo need cystectomy? #SWOGonc
🚨 #Lungcancer breakthroughs at #ESTRO25!
From osimertinib after chemoRT in unresectable EGFR-mutant NSCLC to #SBRT dose precision and ctDNA insights post-SABR, the lung sessions delivered key updates on optimising treatment and tracking response.
👉 bit.ly/4mT4vdI
From osimertinib after chemoRT in unresectable EGFR-mutant NSCLC to #SBRT dose precision and ctDNA insights post-SABR, the lung sessions delivered key updates on optimising treatment and tracking response.
👉 bit.ly/4mT4vdI
August 28, 2025 at 7:44 AM
🚨 #Lungcancer breakthroughs at #ESTRO25!
From osimertinib after chemoRT in unresectable EGFR-mutant NSCLC to #SBRT dose precision and ctDNA insights post-SABR, the lung sessions delivered key updates on optimising treatment and tracking response.
👉 bit.ly/4mT4vdI
From osimertinib after chemoRT in unresectable EGFR-mutant NSCLC to #SBRT dose precision and ctDNA insights post-SABR, the lung sessions delivered key updates on optimising treatment and tracking response.
👉 bit.ly/4mT4vdI